Vulinacimab - CAS 2250342-36-8

Vulinacimab (HLX-06), an anti-VEGFR-2 monoclonal antibody (mAb), plays a pivotal role in cancer research due to VEGFR-2's significant involvement in angiogenesis, as well as the proliferation, survival, migration, and differentiation of endothelial cells, processes critical for tumor growth where VEGFR-2 is overexpressed [1].

VEGFR

Tyrosine Kinase/Adaptors, Angiogenesis

2250298

-20°C

Ice Packs

Inhibitory Antibodies